Clinical trials
Metastatic Cancer clinical trials
Below are recruiting metastatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,866 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05096923Recruiting
Research study for young people with cancer and survivors
This study follows children, teens, and young adults with cancer and people who have completed treatment. It aims to better understand cancer care over time and what affects outcomes, which may help improve future treatment and follow-up.
Chapel Hill, North CarolinaAges 1–39 - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT00068003Enrolling by invitation
Harvesting Cancer Cells for Experimental Treatment
This trial collects immune cells from cancer patients or healthy volunteers to develop new experimental cancer treatments. Researchers will take a sample of your tumor or blood cells, grow them in the lab, and study how to use them to fight your cancer.
Bethesda, MarylandAges 18 years+ - NCT05732051RecruitingPhase 2
Nicotinamide riboside to protect the heart during breast cancer chemo
This trial tests whether nicotinamide riboside can help prevent heart problems caused by a common breast-cancer chemotherapy (anthracyclines). If you’re eligible, you’ll be followed to see how your heart is doing during treatment.
Lørenskog, AkershusAges 18 years+ - NCT07686016Recruiting
Radiation therapy for prostate cancer that has spread to a few spots
This trial studies the use of radiation to the prostate and to all visible spots where cancer has spread, in men who have up to 10 small areas of spread when first diagnosed. The goal is to see if this approach can help control the cancer.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT06951997RecruitingPhase 2
First treatment for metastatic pancreatic cancer using three drugs
This trial tests a new combination of three drugs (QL1706, chidamide, and AG) as the very first treatment for people with metastatic pancreatic cancer. The goal is to see if this combination is safe and effective, and it may offer a new option for those who have not had any prior therapy.
TianjinAges 18–75 - NCT06936527Enrolling by invitationPhase 1/Phase 2
XS-03 plus chemotherapy and bevacizumab for metastatic colorectal cancer with RAS mutation
This trial tests an experimental drug called XS-03 combined with standard chemotherapy (FOLFOX or FOLFIRI) plus a targeted therapy (bevacizumab) for people with metastatic colorectal cancer that has a RAS mutation. The goal is to see if adding XS-03 helps shrink tumors or slows cancer growth better than current treatments.
BeijingAges 18–75 - NCT06583070Recruiting
SABR plus targeted therapy and immunotherapy for advanced kidney cancer
This trial tests combining a precise type of radiation (SABR) with standard targeted therapy and immunotherapy drugs for kidney cancer that has come back or spread. The goal is to see if adding radiation improves outcomes.
Beijing, Beijing MunicipalityAges 18–85 - NCT06343402RecruitingPhase 1
Study of BBO-8520 for advanced KRAS G12C lung cancer
This trial tests a new oral medication called BBO-8520 for advanced lung cancer with a specific gene change (KRAS G12C mutation). It aims to see if the drug is safe and effective, and may be combined with another drug (pembrolizumab) in some groups.
Birmingham, AlabamaAges 18 years+ - NCT05570994Enrolling by invitationPhase 1/Phase 2
PSMA-targeted radioactive drug for advanced prostate cancer
This Phase 1/2 study tests a radioactive treatment that targets PSMA, a protein often found on prostate cancer cells. It’s for men whose prostate cancer has worsened despite hormone-blocking pills like abiraterone or enzalutamide, aiming to help shrink or control the disease.
Vancouver, British ColumbiaAges 18 years+ - NCT05452005RecruitingPhase 1
PET scan with a new tracer for lung cancer brain metastases
This Phase 1 study tests whether a specialized PET scan tracer can “light up” metastatic non-small cell lung cancer in the brain. If you join, you’ll get brain MRI and PET/CT scans and you’ll continue with your planned cancer treatments and follow-up imaging.
Sacramento, CaliforniaAges 18 years+ - NCT05183126RecruitingPhase 4
Paclitaxel dose study using a 1-hour muscle-area infusion
This trial studies how paclitaxel (a chemotherapy medicine) behaves in the body when given by a specific 1-hour infusion approach. It may help refine dosing for people with cancer using measurements from scans, and it includes a medicine schedule you must match.
Ann Arbor, MichiganAges 18 years+ - NCT06820463RecruitingPhase 2
Study of telisotuzumab adizutecan plus chemo for metastatic colorectal cancer
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
Duarte, CaliforniaAges 18 years+ - NCT05334459Recruiting
Radiation and medicines after surgery for new metastatic breast cancer
This trial looks at giving radiation and anti-cancer medicines after surgery to treat newly diagnosed (de novo) metastatic breast cancer. It may help patients by improving local control of the breast area while also treating cancer throughout the body.
AnkaraAges 18–80 - NCT04263298RecruitingPhase 3
Fulvestrant or capecitabine after chemo for metastatic breast cancer
This Phase 3 trial compares two medicines—fulvestrant versus capecitabine—as “maintenance” treatment after your first chemo helps control metastatic breast cancer. It aims to see which one helps people live longer with better disease control.
Guangzhou, GuangdongAges 18–75 - NCT05725200RecruitingPhase 2
Personalized treatment plan for metastatic colon or rectal cancer
This Phase 2 trial tests an individualized treatment chosen from your tumor’s lab testing (genetic and RNA profile plus a drug-sensitivity test from your tumor cells). It may help by matching you to targeted anti-cancer drugs that are most likely to work for your specific cancer.
OsloAges 18 years+ - NCT05753657RecruitingEarly Phase 1
Testing insulin and blood sugar monitoring with pioglitazone
This early study tests whether adding pioglitazone, along with close blood-sugar (glucose/insulin) monitoring, can help control high insulin and high blood sugar in people starting alpelisib for metastatic breast cancer. It may help reduce blood-sugar side effects from alpelisib.
HaifaAges 18–85 - NCT06118762RecruitingPhase 4
Study of fruquintinib plus raltitrexed for advanced colorectal cancer
This trial tests two drugs, fruquintinib and raltitrexed, for people with metastatic colorectal cancer that has stopped responding to or is no longer tolerable after standard treatments like fluorouracil, oxaliplatin, and irinotecan. The goal is to see if this combination can help shrink or control the cancer.
Nanchang, JiangxiAges 18 years+ - NCT05360277RecruitingPhase 2
Maintenance immunotherapy and chemo after surgery for metastatic colon cancer
This Phase 2 trial studies tislelizumab plus capecitabine given after surgery to help prevent metastatic colorectal cancer from coming back. It may be an option if you recently had surgery that removed visible disease and you have good overall health.
Guangzhou, GuangdongAges 18–80 - NCT06218810RecruitingPhase 2
Combination therapy for advanced MSS, RAS-mutated colorectal cancer
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
ShanghaiAges 18–75 - NCT06242067RecruitingPhase 2
Second-line treatment for advanced colorectal cancer
This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.
Jinan, ShandongAges 18–75 - NCT05007132RecruitingPhase 2
First-line metastatic colon or rectal cancer study with targeted drugs
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
BerlinAges 18 years+ - NCT06449937Recruiting
Local liver treatment for colorectal cancer that has spread
This trial tests whether treating liver tumors with surgery or ablation can help people whose colorectal cancer has spread to the liver and other organs. It may be an option if you've had only 1 or 2 types of chemotherapy and your non-liver metastases are stable.
Chuzhou, AnhuiAges 18–80 - NCT06473259Recruiting
Comparing treatments for hormone-sensitive metastatic prostate cancer
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
Orbassano, TorinoAges Any age
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic cancer?
- Yes. Clin2 currently lists 1,866 recruiting metastatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.